The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)

KRAS is a frequent oncogenic driver in solid tumors, including non-small cell lung cancer (NSCLC). It was previously thought to be an “undruggable” target due to the lack of deep binding pockets for specific small-molecule inhibitors. A better understanding of the mechanisms that drive KRAS transfor...

Descripción completa

Detalles Bibliográficos
Autores principales: Salgia, Ravi, Pharaon, Rebecca, Mambetsariev, Isa, Nam, Arin, Sattler, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817862/
https://www.ncbi.nlm.nih.gov/pubmed/33521700
http://dx.doi.org/10.1016/j.xcrm.2020.100186
_version_ 1783638722127855616
author Salgia, Ravi
Pharaon, Rebecca
Mambetsariev, Isa
Nam, Arin
Sattler, Martin
author_facet Salgia, Ravi
Pharaon, Rebecca
Mambetsariev, Isa
Nam, Arin
Sattler, Martin
author_sort Salgia, Ravi
collection PubMed
description KRAS is a frequent oncogenic driver in solid tumors, including non-small cell lung cancer (NSCLC). It was previously thought to be an “undruggable” target due to the lack of deep binding pockets for specific small-molecule inhibitors. A better understanding of the mechanisms that drive KRAS transformation, improved KRAS-targeted drugs, and immunological approaches that aim at yielding immune responses against KRAS neoantigens have sparked a race for approved therapies. Few treatments are available for KRAS mutant NSCLC patients, and several approaches are being tested in clinicals trials to fill this void. Here, we review promising therapeutics tested for KRAS mutant NSCLC.
format Online
Article
Text
id pubmed-7817862
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-78178622021-01-29 The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC) Salgia, Ravi Pharaon, Rebecca Mambetsariev, Isa Nam, Arin Sattler, Martin Cell Rep Med Review KRAS is a frequent oncogenic driver in solid tumors, including non-small cell lung cancer (NSCLC). It was previously thought to be an “undruggable” target due to the lack of deep binding pockets for specific small-molecule inhibitors. A better understanding of the mechanisms that drive KRAS transformation, improved KRAS-targeted drugs, and immunological approaches that aim at yielding immune responses against KRAS neoantigens have sparked a race for approved therapies. Few treatments are available for KRAS mutant NSCLC patients, and several approaches are being tested in clinicals trials to fill this void. Here, we review promising therapeutics tested for KRAS mutant NSCLC. Elsevier 2021-01-19 /pmc/articles/PMC7817862/ /pubmed/33521700 http://dx.doi.org/10.1016/j.xcrm.2020.100186 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Salgia, Ravi
Pharaon, Rebecca
Mambetsariev, Isa
Nam, Arin
Sattler, Martin
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
title The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
title_full The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
title_fullStr The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
title_full_unstemmed The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
title_short The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
title_sort improbable targeted therapy: kras as an emerging target in non-small cell lung cancer (nsclc)
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817862/
https://www.ncbi.nlm.nih.gov/pubmed/33521700
http://dx.doi.org/10.1016/j.xcrm.2020.100186
work_keys_str_mv AT salgiaravi theimprobabletargetedtherapykrasasanemergingtargetinnonsmallcelllungcancernsclc
AT pharaonrebecca theimprobabletargetedtherapykrasasanemergingtargetinnonsmallcelllungcancernsclc
AT mambetsarievisa theimprobabletargetedtherapykrasasanemergingtargetinnonsmallcelllungcancernsclc
AT namarin theimprobabletargetedtherapykrasasanemergingtargetinnonsmallcelllungcancernsclc
AT sattlermartin theimprobabletargetedtherapykrasasanemergingtargetinnonsmallcelllungcancernsclc
AT salgiaravi improbabletargetedtherapykrasasanemergingtargetinnonsmallcelllungcancernsclc
AT pharaonrebecca improbabletargetedtherapykrasasanemergingtargetinnonsmallcelllungcancernsclc
AT mambetsarievisa improbabletargetedtherapykrasasanemergingtargetinnonsmallcelllungcancernsclc
AT namarin improbabletargetedtherapykrasasanemergingtargetinnonsmallcelllungcancernsclc
AT sattlermartin improbabletargetedtherapykrasasanemergingtargetinnonsmallcelllungcancernsclc

Ejemplares similares